Efficacy of biofeedback in treatment of migraine
DOI:
https://doi.org/10.18203/2320-6012.ijrms20230338Keywords:
Conventional, Frequency, Headache, Pharmacotherapy, SeverityAbstract
Background: Migraine is characterized by increased excitability of CNS. Biofeedback is a non-invasive, non-pharmacologic therapeutic technique, which helps patients control stress response by deep breathing,visualization and medication. The aim of the study was to compare efficacy of conventional therapy, biofeedback and combination of pharmacotherapy with biofeedback.
Methods: This is a randomized study conducted for period of 2 years from April 2020 to May 2022 in Srinivas Institute of Medical Science and Research Centre, Mukka, Surathkal. 100 patients who were diagnosed with migraine between 18 and 60 years of age were included in the study after ruling out other primary causes of headache. Patients<18 years of age >60 years of age, with known comorbidities that can precipitate headache and on treatment for any other condition were excluded from the study. They were randomly assigned to groups for receiving conventional therapy, biofeedback therapy and combination of pharmacotherapy and biofeedback. 35 patients were allotted to group which received conventional therapy, 35 were assigned to the group that received combination of biofeedback and pharmacotherapy and 30 patients were allotted to the group that received biofeedback alone.
Results: Among 100 migraine patients 58 were females and 42 were males. 62 of them were in the age group of 30 to 40 years of age. 66 patients belonged to moderate to severe category of migraine. Out of 35 patients who received conventional therapy 21 (57.4%) reported improvement in quality of life, whereas 26 out of 35 (74.28%) who received combination of biofeedback and pharmacotherapy reported reduction in severity and frequency of headaches with better quality of life compared to 13 patients out of 30 who received biofeedback alone (43.3%).
Conclusions: Patients who received combination of biofeedback and pharmacotherapy had best outcome (74.28%) compared to the ones who received biofeedback (43.3%) or conventional therapy (57.4%) alone.
Metrics
References
Mullally WJ, Hall K, Goldstein R. Efficacy of biofeedback in the treatment of migraine and tension type headaches. Pain Physician. 2009;12(6):1005-11.
The Medical Roundtable. Behavioral Approaches to Headache and Migraine Management. Gen Med. 2017;1(2):131-44.
Sullivan A, Cousins S, Ridsdale L. Psychological interventions for migraine: A systematic review. J Neurol. 2016;263:2369-77.
Zivoder I, Biocina SM, Kosic V. Biofeedback and Neurofeedback in the Treatment of Migraine. Intechopen. 2017.
Stokes DA, Lappin MS. Neurofeedback and biofeedback with 37 migraineurs: a clinical outcome study. Behav Brain Funct. 2010;6:9.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9.
Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol. 2006;13(4):333-45.
Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57(3):418-20.
Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med (Lond). 2015;15(4):344-50.
Vasudeva S, Claggett AL, Tietjen GE, McGrady AV. Biofeedback-assisted relaxation in migraine headache: relationship to cerebral blood flow velocity in the middle cerebral artery. Headache. 2003;43(3):245-50.
Kropp P, Meyer B, Dresler T, Fritsche G, Gaul C, Niederberger U. Relaxation techniques and behavioural therapy for the treatment of migraine : Guidelines from the German Migraine and Headache Society. Schmerz. 2017;31(5):433-47.
Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache. 2005;45(2):S92-109.
Langenbahn D, Matsuzawa Y, Lee YSC, Fraser F, Penzien DB, Simon NM, et al. Underuse of Behavioral Treatments for Headache: a Narrative Review Examining Societal and Cultural Factors. J Gen Intern Med. 2021;36(10):3103-12.
Diest AM, Powers SW. Cognitive Behavioral Therapy for Pediatric Headache and Migraine: Why to Prescribe and What New Research Is Critical for Advancing Integrated Biobehavioral Care. Headache. 2019;59(2):289-97.
Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622-30.
Kroner JW, Hershey AD, Kashikar-Zuck SM, LeCates SL, Allen JR, Slater SK, et al. Cognitive Behavioral Therapy plus Amitriptyline for Children and Adolescents with Chronic Migraine Reduces Headache Days to ≤4 Per Month. Headache. 2016;56(4):711-6.
Downloads
Published
How to Cite
Issue
Section
